Publication | Open Access

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint InhibitorIpilimumab Versus SunitinibPharmacotherapySafety ResultsCancer TreatmentOncologyPhase 3